11/13
09:45 am
imvt
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
Medium
Report
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
11/8
11:57 am
imvt
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
11/8
08:46 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
11/7
06:30 am
imvt
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Low
Report
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
10/29
06:30 am
imvt
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Low
Report
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
10/14
02:58 pm
imvt
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
Low
Report
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
10/10
09:36 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
10/9
08:40 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.
9/30
08:01 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
9/23
08:00 am
imvt
Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
Medium
Report
Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
9/10
08:01 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
9/9
05:46 pm
imvt
Immunovant stock falls 8% amid Graves' disease program update Sep. 09, 2024 5:18 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
Medium
Report
Immunovant stock falls 8% amid Graves' disease program update Sep. 09, 2024 5:18 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
9/9
02:14 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
12:59 pm
imvt
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? [Yahoo! Finance]
Medium
Report
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? [Yahoo! Finance]
9/9
10:14 am
imvt
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab [Yahoo! Finance]
Medium
Report
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab [Yahoo! Finance]
9/9
08:32 am
imvt
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses [Yahoo! Finance]
Medium
Report
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses [Yahoo! Finance]
9/9
04:09 am
imvt
Immunovant Provides Update on Graves' Disease Development Program [Yahoo! Finance]
Medium
Report
Immunovant Provides Update on Graves' Disease Development Program [Yahoo! Finance]
9/9
03:55 am
imvt
Immunovant Provides Update on Graves’ Disease Development Program
Medium
Report
Immunovant Provides Update on Graves’ Disease Development Program
9/5
12:54 pm
imvt
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? [Yahoo! Finance]
Medium
Report
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? [Yahoo! Finance]
9/5
06:30 am
imvt
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
Medium
Report
Immunovant to Host Graves’ Disease Program Update on September 9, 2024